Developing next-generation NK cell and innate lymphoid cell therapeutics for oncology and auto-immune disease. By utilizing highly innovative macrocyclic multi-specific cell engagers, Nickl aims to redirect the cytotoxic capabilities of NK cells for the precision killing of disease-mediating cells across a number of therapeutic settings.

Initial focus is on the activation of the innate immune system within the microenvironment of solid tumors to enhance cancer cell killing and provide improved patient outcomes in indications with significant unmet need.